Scarica l'app Stockscreener
0.00
100.00%
-3.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVNC Giù?
Forum
Previsione
Revance Therapeutics Inc Borsa (RVNC) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesRVNC - PR Newswire
Deadline Alert: Revance Therapeutics, Inc. (RVNC) Investors - GlobeNewswire
2025-02-11 | Shareholders that lost money on Revance Therapeutics, Inc. (RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC | Press Release - Stockhouse Publishing
2025-02-10 | Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Should Contact Levi & Korsinsky about Pending Class ActionRVNC | Press Release - Stockhouse Publishing
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
2025-02-10 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming Deadline | Press Release - Stockhouse Publishing
2025-02-10 | RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | Press Release - Stockhouse Publishing
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders - PR Newswire
Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
2025-02-09 | Class Action Filed Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 Deadline to JoinContact Levi & Korsinsky | Press Release - Stockhouse Publishing
Deltec Asset Management LLC Makes New $304,000 Investment in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - ETF Daily News
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by SG Americas Securities LLC - Defense World
Revance Therapeutics (NASDAQ:RVNC) Completes Merger with Crown Laboratories - Defense World
Crown Labs completes acquisition of Revance Therapeutics - MSN
Crown Laboratories Completes Acquisition of Revance Therapeutics - BioSpace
Major Aesthetics Industry Shakeup: Crown Labs Takes Over Revance in Strategic Power Move - StockTitan
Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - The Malaysian Reserve
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria
GLAZER CAPITAL, LLC Acquires Significant Stake in Revance Therap - GuruFocus.com
DEADLINE ALERT for RVNC, REGN, and BIOA: The Law Offices of - GlobeNewswire
Revance Therapeutics Finalizes Merger with Crown Laboratories - MSN
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Revance’s acquisition by Crown Laboratories completed - TipRanks
Major Aesthetics Deal: Crown Labs Acquires Revance as Shareholders Cash Out at Premium - StockTitan
The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Taking a Closer Look At Revance Therapeutics Inc (RVNC) Following Its Recent Trade - Knox Daily
Lawsuit Alert: Investors who lost money with shares of Revance - openPR
Revance Therapeutics sells to Crown Laboratories - The Business Journals
Revance Therapeutics Inc’s Shares Reel: -37.07% Quarterly Revenue Decline Amid 381.02M Market Cap - The InvestChronicle
Revance Therapeutics, Crown Laboratories Announce Expiration of Tender Offer -February 05, 2025 at 10:39 am EST - Marketscreener.com
Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer - Marketscreener.com
Major Biotech Deal: Revance Shareholders Back Crown Labs Takeover with Massive 82% Support Rate - StockTitan
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class ActionRVNC - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Revance - GlobeNewswire
ForexTV | Small Business Resources - ForexTV.com
RVNC INVESTOR ALERT: Kirby McInerney LLP Notifies Revance Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit - yourbigsky.com
Levi & Korsinsky Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 – RVNC - yourbigsky.com
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your RightsRVNC - PR Newswire
RVNC LAWSUIT ALERT: Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
2025-02-03 | Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) - GuruFocus.com
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class ActionRVNC - PR Newswire
Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC - ACCESS Newswire
2025-02-02 | Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
2025-02-01 | Levi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline | NDAQ:RVNC | Press Release - Stockhouse Publishing
Mizuho maintains neutral on Revance, price target steady at $3.65 - MSN
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Teoxane withdraws takeover offer for Revance Therapeutics - MSN
2025-01-31 | Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineRVNC | NDAQ:RVNC | Press Release - Stockhouse Publishing
2.27%
5.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):